Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Dyne Therapeutics Inc (DYN)

Dyne Therapeutics Inc (DYN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,101,223
  • Shares Outstanding, K 87,383
  • Annual Sales, $ 0 K
  • Annual Income, $ -235,940 K
  • 60-Month Beta 1.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.36
Trade DYN with:

Options Overview Details

View History
  • Implied Volatility 58.06% ( -3.23%)
  • Historical Volatility 89.38%
  • IV Percentile 5%
  • IV Rank 5.89%
  • IV High 350.04% on 11/10/23
  • IV Low 39.80% on 06/18/24
  • Put/Call Vol Ratio 0.56
  • Today's Volume 28
  • Volume Avg (30-Day) 91
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 2,721
  • Open Int (30-Day) 9,042

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.72
  • Number of Estimates 8
  • High Estimate -0.59
  • Low Estimate -0.97
  • Prior Year -1.08
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.75 +16.47%
on 06/10/24
36.60 -5.33%
on 06/24/24
+2.77 (+8.69%)
since 05/31/24
3-Month
23.11 +49.94%
on 04/19/24
36.60 -5.33%
on 06/24/24
+6.81 (+24.46%)
since 04/02/24
52-Week
6.40 +441.41%
on 10/30/23
36.60 -5.33%
on 06/24/24
+23.40 (+208.00%)
since 06/30/23

Most Recent Stories

More News
Why Shares of Dyne Therapeutics Fell This Week

Insiders sold more than 15,000 shares of company stock on Tuesday.

DYN : 34.65 (-2.37%)
Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

- FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx Model - WALTHAM, Mass., Aug. 10, 2022 ...

DYN : 34.65 (-2.37%)
Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 - WALTHAM, Mass.,...

DYN : 34.65 (-2.37%)
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

- Initiation of Dosing in Multiple Ascending Dose Clinical Trial of DYNE-101 in Patients with DM1 On Track for Mid-2022 - - Executing on Global Clinical...

DYN : 34.65 (-2.37%)
Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

- Initiation of Dosing in Multiple Ascending Dose Clinical Trial in Patients with Mutations Amenable to Skipping Exon 51 On Track for Mid-2022 - WALTHAM,...

DYN : 34.65 (-2.37%)
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

WALTHAM, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative...

DYN : 34.65 (-2.37%)
Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown

- Initiation of Dosing in Multiple Ascending Dose Clinical Trial for DYNE-101 in Patients with Myotonic Dystrophy Type 1 Anticipated in Mid-2022 - ...

DYN : 34.65 (-2.37%)
Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Anticipated in Mid-2022 - WALTHAM,...

DYN : 34.65 (-2.37%)
selfologi Chooses Digital Technology Consulting Partner Grid Dynamics to Launch Its Cosmetic Treatment Platform

SAN RAMON, CA / ACCESSWIRE / March 17, 2022 / Grid Dynamics Holdings, Inc. (NASDAQ:DYN) (Grid Dynamics), a leader in enterprise-level digital engineering services and solutions, today announced it has...

DYN : 34.65 (-2.37%)
GDYN : 10.57 (+2.13%)
Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

- Response to FDA for DYNE-251 IND in DMD on Track for Submission in the Second Quarter of 2022 -- Initiation of Patient Dosing in Multiple Ascending Dose...

DYN : 34.65 (-2.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 36.56
2nd Resistance Point 36.00
1st Resistance Point 35.32
Last Price 34.65
1st Support Level 34.08
2nd Support Level 33.52
3rd Support Level 32.85

See More

52-Week High 36.60
Last Price 34.65
Fibonacci 61.8% 25.06
Fibonacci 50% 21.50
Fibonacci 38.2% 17.94
52-Week Low 6.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar